Evidence-Based Reviews

Catatonia: How to identify and treat it

Author and Disclosure Information

 

References

Among other neurologic syndromes that can be confused with catatonia, locked-in syndrome consists of total immobility except for vertical extraocular movements and blinking. In this state, patients attempt to communicate with their eyes, while catatonic patients do not try to communicate. There is no response to a lorazepam challenge test. Stiff man syndrome is associated with painful spasms precipitated by touch, noise, or emotional stimuli. Baclofen can resolve stiff man syndrome, but it can induce catatonia. Paratonia refers to generalized increased motor tone that is idiopathic, or associated with neurodegeneration, encephalopathy, or medications. The only motor sign is increased tone, and other signs of catatonia are absent. Catatonia is usually associated with some motor behaviors and interaction with the environment, even if it is negative, while the coma vigil patient is completely unresponsive. Frontotemporal dementia is progressive, while catatonia usually improves without residual dementia.30

Benzodiazepines, ECT are the usual treatments

Experience dictates that the general principles of treatment noted in Table 712,15,23,31 apply to all patients with catatonia. Since the first reported improvement of catatonia with amobarbital in 1930,6 there have been no controlled studies of specific treatments of catatonia.13 Meaningful treatment trials are either naturalistic, or have been performed only for NMS and malignant catatonia.5 However, multiple case reports and case series suggest that treatments with agents that have anticonvulsant properties (benzodiazepines, barbiturates) and ECT are effective.5

Principles of treatment of catatonia

Benzodiazepines and related compounds. Case series have suggested a 60% to 80% remission rate of catatonia with benzodiazepines, the most commonly utilized of which has been lorazepam.7,13,32 Treatment begins with a lorazepam challenge test of 1 to 2 mg in adults and 0.5 to 1 mg in children and geriatric patients,9,15 administered orally (including via nasogastric tube), IM, or IV. Following a response (≥50% improvement), the dose is increased to 2 mg 3 times per day. The dose is further increased to 6 to 16 mg/d, and sometimes up to 30 mg/d.9,11 Oral is less effective than sublingual or IM administration.11 Diazepam can be helpful at doses 5 times the lorazepam dose.9,17 A zolpidem challenge test of 10 mg orally or via nasogastric tube has also been utilized.15 Response is brief and is usually followed by lorazepam, although zolpidem up to 40 mg/d has been used for ongoing treatment.9

One alternative benzodiazepine protocol utilizes an initial IV dose of 2 mg lorazepam, repeated 3 to 5 times per day; the dose is increased to 10 to 12 mg/d if the first doses are partially effective.16 A lorazepam/diazepam approach involves a combination of IM lorazepam and IV diazepam.11 The protocol begins with 2 mg of IM lorazepam. If there is no effect within 2 hours, a second 2 mg dose is administered, followed by an IV infusion of 10 mg diazepam in 500 ml of normal saline at 1.25 mg/hour until catatonia remits.

An Indian study of 107 patients (mean age 26) receiving relatively low doses of lorazepam (3 to 6 mg/d for at least 3 days) found that factors suggesting a robust response include a shorter duration of catatonia and waxy flexibility, while passivity, mutism, and auditory hallucinations describing the patient in the third person were associated with a poorer acute response.31 Catatonia with marked retardation and mutism complicating schizophrenia, especially with chronic negative symptoms, may be associated with a lower response rate to benzodiazepines.20,33 Maintenance lorazepam has been effective in reducing relapse and recurrence.11 There are no controlled studies of maintenance treatment with benzodiazepines, but clinical reports suggest that doses in the range of 4 to 10 mg/d are effective.32

Continue to: ECT was used for catatonia in 1934...

Pages

Recommended Reading

Comorbidities provide possible path to schizophrenia subtypes
MDedge Psychiatry
Suicidal ideation, maladaptive beliefs appear linked in some psychotic disorders
MDedge Psychiatry
A call for psychiatrists with tardive dyskinesia expertise
MDedge Psychiatry
Dr. Dinah Miller, Dr. Annette Hanson on involuntary psychiatric care
MDedge Psychiatry
Sudden-onset memory problems, visual hallucinations, and odd behaviors
MDedge Psychiatry
Antipsychotics linked to increased body fat, insulin resistance in children
MDedge Psychiatry
Long-acting injectable antipsychotics: What to do about missed doses
MDedge Psychiatry
FDA approves Aristada Initio for schizophrenia
MDedge Psychiatry
Fetal exposure to folic acid may reduce youth psychosis risk
MDedge Psychiatry
FDA approves Perseris for schizophrenia
MDedge Psychiatry